Volume 59, Issue 10 p. 1899-1907
Clinical Investigations

Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults: A Population-Based Case–Control Study

Sascha Dublin MD, PhD

Corresponding Author

Sascha Dublin MD, PhD

Group Health Research Institute, Seattle, Washington

Epidemiology

Address correspondence to Sascha Dublin, Group Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101. E-mail: [email protected]Search for more papers by this author
Rod L. Walker MS

Rod L. Walker MS

Group Health Research Institute, Seattle, Washington

Search for more papers by this author
Michael L. Jackson PhD, MPH

Michael L. Jackson PhD, MPH

Group Health Research Institute, Seattle, Washington

Search for more papers by this author
Jennifer C. Nelson PhD

Jennifer C. Nelson PhD

Group Health Research Institute, Seattle, Washington

Biostatistics

Search for more papers by this author
Noel S. Weiss MD, PhD

Noel S. Weiss MD, PhD

Epidemiology

Search for more papers by this author
Michael Von Korff ScD

Michael Von Korff ScD

Group Health Research Institute, Seattle, Washington

Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington

Search for more papers by this author
Lisa A. Jackson MD, MPH

Lisa A. Jackson MD, MPH

Group Health Research Institute, Seattle, Washington

Epidemiology

Search for more papers by this author
First published: 13 September 2011
Citations: 131

Abstract

Objectives

To examine whether use of opioids or benzodiazepines is associated with risk of community-acquired pneumonia in older adults.

Design

Population-based case–control study.

Setting

An integrated healthcare delivery system.

Participants

Community-dwelling, immunocompetent adults aged 65 to 94 from 2000 to 2003. Presumptive pneumonia cases were identified from health plan automated data and validated through medical record review. Two controls were selected for each case with pneumonia, matched on age, sex, and calendar year.

Measurements

Information about opioid and benzodiazepine use came from computerized pharmacy data. Information on covariates including comorbid illnesses and functional and cognitive status came from medical record review and electronic health data.

Results

One thousand thirty-nine validated cases of pneumonia and 2,022 matched controls were identified. One hundred forty-four (13.9%) cases and 161 (8.0%) controls used prescription opioids (adjusted odds ratio (OR) = 1.38, 95% confidence interval (CI) = 1.08–1.76 vs nonuse). Risk was highest for opioids categorized as immunosuppressive based on immunological studies (OR = 1.88, 95% CI = 1.26–1.79 vs nonuse), whereas for nonimmunosuppressive opioids the OR was 1.23 (95% CI = 0.89–1.69). Risk was highest in the first 14 days of use (OR = 3.24, 95% CI = 1.64–6.39 vs nonuse). For long-acting opioids, the OR was 3.43 (95% CI = 1.44–8.21) versus nonuse, whereas for short-acting opioids, it was 1.27 (95% CI = 0.98–1.64). No greater risk was seen for current benzodiazepine use compared to nonuse (OR = 1.08, 95% CI = 0.80–1.47).

Conclusion

Use of opioids but not benzodiazepines was associated with pneumonia risk. The differences in risk seen for different opioid regimens warrant further study.